|
| Monday, March 10, 2025 |
|
|
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time |
| Eisai Co., Ltd. announced today that it has been recognized as the 2025 KENKO Investment for Health by Japan's Ministry of Economy, Trade, and Industry (METI) and the Tokyo Stock Exchange, for the first time as a company strategically carrying out efforts with regard to its employees' health from a management perspective. more info >> |
|
| Wednesday, March 5, 2025 |
|
|
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan |
| Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025. more info >> |
|
| Tuesday, March 4, 2025 |
|
|
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia). more info >> |
|
| Monday, March 3, 2025 |
|
|
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell" |
| Eisai Co., Ltd. announced today the launch of the new nutritional drink "Chocola BB Nightwell" (designated quasi-drug product), a nutritional drink to help recovery from the accumulated fatigue of the day during sleep, on Monday, March 3. more info >> |
|
|
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Abeta; monoclonal antibody lecanemab, adopted in November 2024. more info >> |
|
| Friday, February 28, 2025 |
|
|
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone |
| Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched. more info >> |
|
| Thursday, February 20, 2025 |
|
|
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives |
| Eisai Co., Ltd. announced today that it has been selected for "Human CapitalLeaders 2024" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2024" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.), MS&AD InterRisk Research & Consulting, Inc. and Association to Confirm the Human Investment Value for Enterprise. more info >> |
|
| Friday, February 14, 2025 |
|
|
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease |
| Oita University and Eisai Co., Ltd. announced today the development of a machine learning model to predict amyloid beta (Abeta) accumulation in the brain, combining background data such as age, gender, smoking history and medical history, as well as general blood test and MMSE items. more info >> |
|
| Monday, February 3, 2025 |
|
|
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies |
| National Center for Geriatrics and Gerontology and Eisai Co., Ltd. announced today that Eisai has created the "Guidance on Reducing the Risk of Cognitive Decline and Nutrition" and the "Handbook for Developing Home Delivery Meals/Meal Kits that Contribute to Reducing the Risk of Cognitive Decline" under the supervision of NCGG. more info >> |
|
| Tuesday, January 28, 2025 |
|
|
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application (sBLA) for once every four weeks lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
|
|
